Table 3 Ongoing clinical trials of new drug groups in AIHA
From: Autoimmune hemolytic anemia: current knowledge and perspectives
| Intervention/ treatment | Group of agents | Condition or disease | Phase of study | ClinicalTrials.gov |
|---|---|---|---|---|
| Sirolimus plus ATRA | mTOR inhibitor plus tretinoin | refractory AIHA | 2 and 3 | NCT04324411 |
| Idelalisib vs. ibrutinib | PI3Kδ inhibitor vs. BTK inhibitor | autoimmune cytopenia in the course of CLL | retrospective | NCT03469895 |
| Parsaclisib | PI3Kδ inhibitor | AIHA | 2 | NCT03538041 |
| Ibrutinib | BTK inhibitor | steroid refractory warm AIHA | 2 | NCT03827603 |
| refractory/relapsed AIHA | 2 | NCT04398459 | ||
| Ibrutinib or idelalisib | BTK inhibitor | AIHA associated with CLL | retrospective | NCT03469895 |
| Interleukine-2 | cytokine | resistant, warm AIHA | 1 and 2 | NCT02389231 |
| Low dose rituximab plus alemtuzumab | anti CD20 antibody plus anti CD52 antibody | refractory autoimmune cytopenias | 2 and 3 | NCT00749112 |
| Fostamatinib | SYK inhibitor | warm AIHA | 3 | NCT03764618 |
| 2 | NCT02612558 | |||
| SYNT001 (ALXN1830) | anti-FcRn antibody | warm AIHA | 1 and 2 | NCT03075878 |
| SYNT001 (ALXN1830) vs. placebo | 2 | NCT04256148 | ||
| M281 | 2 and 3 | NCT04119050 | ||
| RVT-1401 | 2 | NCT04253236 | ||
| Levamisole plus prednisolone | immunomodulatory drug plus GKS | warm AIHA | 2 | NCT01579110 |
| BIVV009 (Sutimlimab) | complement C1 inhibitor | CAD | 3 | NCT03347422 |
| 3 | NCT03347396 | |||
| APL2 | complement C3 inhibitor | warm AIHA, CAD | 2 | NCT03226678 |